Evidence map›Paper›PMID 31234436›Full record

ArticleCancers2019

Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/Cisplatin.

Madoka Takeuchi, Jaffer A Ajani, Xuemin Fang, Per Pfeiffer, Masahiro Takeuchi, Hanneke W M van Laarhoven

Abstract read
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Madoka TakeuchiFaculty of Environment and Information Studies, Keio University, 5322 Endo, Fujisawa-shi, Kanagawa 252-0882, Japan. madoka.takeuchi@gmail.com.
Jaffer A AjaniGastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA. jajani@mdanderson.org.
Xuemin FangClinical Medicine (Biostatistics), Kitasato University, Tokyo 108-8641, Japan. mindy.fang@gmail.com.
Per PfeifferExperimental research in medical cancer therapy, Odense University Hospital, 5000 Odense C, Denmark. per.pfeiffer@rsyd.dk.
Masahiro TakeuchiClinical Medicine (Biostatistics), Kitasato University, Tokyo 108-8641, Japan. tsmasaamg@gmail.com.
Hanneke W M van LaarhovenDepartment of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands. h.vanlaarhoven@amc.uva.nl.

Funding

Taiho Pharmaceutical null
6 · The paper itself

Abstract

The Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study (FLAGS) and the Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial (DIGEST) have shown that patients with advanced gastric cancer treated with S-1/Cisplatin (CS) have similar overall survival (OS) compared to 5-fluorouracil/cisplatin (CF). The purpose of this analysis was to identify patients who may specifically benefit from CS using meta-enrichment analysis of the combined two datasets. Eleven clinico-pathological factors were selected and a high response enrichable population was determined. The efficacy of CS in the combined data set of 1365 patients (

Indexed as

DIGEST trialFLAGS trialgastric cancerpredictive enrichment strategy analysisS-1

Identifiers

PMID31234436
PMCPMC6627221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.